Rapport Therapeutics director's fund buys 35,714 shares

The weighted average price reflects multiple transactions, with reported purchase prices ranging from $26.87 to $27.84 per share.

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. director Steven M. Paul reported that Paul Capital Strategy III Fund LLC purchased 35,714 shares of common stock on October 22, 2026. The $27.28 per-share weighted average reflects multiple transactions priced from $26.87 to $27.84. After the purchase, the LLC held 77,380 shares. Paul disclaims beneficial ownership of those shares except to the extent of any pecuniary interest; the report also lists 477,642 shares held directly as of October 22, 2026. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 35,714 shares

Net Buy 2 txns

Insider PAUL STEVEN M

Role Director

Bought 35,714 shs ($974K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2	35,714	$27.28	$974K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 77,380 shares (Indirect, By Paul Capital Strategy III Fund LLC); Common Stock — 477,642 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.87 to $27.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.
2. F2. Shares held by Paul Capital Strategy III Fund LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.

Key Figures

Common shares purchased: 35,714 shares Weighted average purchase price: $27.28 per share Purchase price range: $26.87 to $27.84 per share +2 more

5 metrics

Common shares purchased 35,714 shares Paul Capital Strategy III Fund LLC, October 22, 2026

Weighted average purchase price $27.28 per share Multiple transactions on October 22, 2026

Purchase price range $26.87 to $27.84 per share Multiple transactions on October 22, 2026

Shares held by Paul Capital Strategy III Fund LLC after purchase 77,380 shares October 22, 2026

Shares held directly by Steven M. Paul 477,642 shares October 22, 2026

Key Terms

weighted average price, beneficial ownership, pecuniary interest

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership regulatory

"The Reporting Person disclaims beneficial ownership of these shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest therein, if any."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RAPP shares did Steven M. Paul's fund purchase?

Paul Capital Strategy III Fund LLC purchased 35,714 shares of Rapport Therapeutics common stock on October 22, 2026, at a weighted average of $27.28 per share. The transactions were priced from $26.87 to $27.84, inclusive. No Rule 10b5-1 plan is reported.

Who held the RAPP shares purchased in the report?

The purchased shares were held by Paul Capital Strategy III Fund LLC. Steven M. Paul disclaims beneficial ownership of those shares except to the extent of his pecuniary interest, if any. The report separately lists 477,642 shares held directly as of October 22, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/22/2026 - 04:57 PM EDT Accepted by SEC EDGAR 10/22/2026 - 04:56 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PAUL STEVEN M

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/22/2026		P		35,714	A	$27.28(1)	77,380	I	By Paul Capital Strategy III Fund LLC(2)
Common Stock								477,642	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.87 to $27.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.

2. Shares held by Paul Capital Strategy III Fund LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.

	/s/ Troy Ignelzi, Attorney-in-Fact	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)